Liquidia Technologies Inc (LQDA)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
LQDA
Liquidia Technologies Inc
$68.64
+3.33%
HEALTHCARE · Cap: $5.95B
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.95
+0.32%
HEALTHCARE · Cap: $60.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 1024265% more annual revenue ($4.62T vs $450.91M). LQDA leads profitability with a 30.7% profit margin vs -3.5%. LQDA earns a higher WallStSmart Score of 60/100 (C).
LQDA
Buy60
out of 100
Grade: C
TAK
Buy53
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 49.8%
Revenue surging 1843.0% year-over-year
Every $100 of equity generates 28 in profit
Growing faster than its price suggests
Reasonable price relative to book value
Generating 73.8B in free cash flow
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 31.3x book value
Distress zone — elevated risk
ROE of 2.4% — below average capital efficiency
Earnings declined 9.8%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : LQDA
The strongest argument for LQDA centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 30.7% and operating margin at 49.8%. Revenue growth of 1843.0% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bear Case : LQDA
The primary concerns for LQDA are EPS Growth, P/E Ratio, Price/Book. A P/E of 47.5x leaves little room for execution misses.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
LQDA profiles as a growth stock while TAK is a turnaround play — different risk/reward profiles.
LQDA carries more volatility with a beta of 0.54 — expect wider price swings.
LQDA is growing revenue faster at 1843.0% — sustainability is the question.
TAK generates stronger free cash flow (73.8B), providing more financial flexibility.
Bottom Line
LQDA scores higher overall (60/100 vs 53/100), backed by strong 30.7% margins and 1843.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?